Advancing peptides for the treatment of rare endocrine and metabolic disorders Amolyt Pharma is building on its team’s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma’s portfolio includes AZP-3601, a parathyroid hormone analog for the potential treatment … [voir plus]

Scale Drug Discovery with Quantum-inspired Physics and AI Aqemia is a pharmatech company using quantum physics and artificial intelligence to transform the drug discovery process. With a unique proprietary technology that preclude the use of experimental data, our pipeline scales the drug discovery process at an unprecedented pace, generating an … [voir plus]

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. [voir plus]

Cardiawave is developing an innovative and non-invasive ultrasound treatment of aortic stenosis. Innovation prize winner of many contests, Cardiawave is a clinical-stage company which develops an innovative non-invasive image-guided medical device (MD) to treat aortic valve stenosis with ultrasound technology. Aortic stenosis is a life-threatening disease which is a major … [voir plus]

CorWave develops innovative implantable blood pumps based on a breakthrough membrane technology. CorWave is a medical device company developing innovative heart pumps (Left Ventricular Assist Devices, LVADs). Our mission is to lower the burden associated with LVADs by curbing pump-related adverse events and reducing the invasiveness of the surgery. We … [voir plus]

Transforming how molecular biology translates to human health, personalized medicine and synthetic biology DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX™️, the world’s … [voir plus]

Dynacure is a clinical-stage company focused on developing novel therapies for rare diseases. Dynacure is a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Dynacure is developing DYN101, an investigational antisense product candidate … [voir plus]

Microbiome Decoded - Healthcare Transformed We are a clinical stage biopharmaceutical company developing first in class drugs based on our unique ability to de-code molecular interactions in the gut microbiome impacting human health. We have developed two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer … [voir plus]

Developing therapeutics for diseases with impaired kidney function ENYO Pharma est une entreprise au stade clinique ayant une approche innovante inspirée par les virus. Notre biotech imite les stratégies virales permettant ainsi de moduler les fonctions cellulaires pour des indications thérapeutiques variées. Nous développons de nouveaux médicaments candidats dans plusieurs … [voir plus]

The CDMO for extracellular vesicle and exosome manufacturing. EverZom is a nanomedecine biotech companies developing a GMP compliant extracellular vesicle manufacturing platform based on a unique proprietary technology for pharmaceutical researchers developing breakthrough biotherapies. Extracellular vesicles which encompass exosomes, microvesicles and apoptotic bodies are the tools used by cells to … [voir plus]

We create ophthalmic therapeutic bio factories to sustainably treat major eye diseases. Eyevensys is a clinical stage, private, biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease. EyeCET stands for the eye ciliary muscle electro-transfection … [voir plus]

Fab’entech is a privately owned biopharmaceutical SME based in Lyon (France) and created in 2009, which develops immunotherapies to address situations of emergency. In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be … [voir plus]

Faircraft develops a highly sustainable, lab-grown alternative to animal leather. Faircraft develops a highly sustainable, lab-grown alternative to animal leather, based on advanced tissue engineering and material science techniques. [voir plus]

A regenerative medecine company Healshape is a regenerative medecine project. We aim at developing breast regeneration solutions by 3D bioprinting for women who had mastectomy following breast cancer. Biotechnology, Regenerative medecine, Médecine régénérative, Reconstruction mammaire, Cancer du sein, Breast cancer, Breast regeneration, Breast reconstruction, 3D bioprinting, Tissue engineering, Biologie cellulaire, … [voir plus]

Igyxos develop more effective/efficient infertility treatment for patients Igyxos is a biotechnology company based out of CENTRE INRAe VAL DE LOIRE SITE DE TOURS, NOUZILLY, France. Biotechnologie, Fertilité, and anticorps monoclonal [voir plus]

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, … [voir plus]

Control innate immunity Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced … [voir plus]

L'intelligence artificielle au service de la biologie médicale Kiro est une startup en pleine croissance qui développe des solutions d’intelligence artificielle pour la biologie médicale. Nous cherchons à améliorer l'expérience du parcours de soins en fournissant des informations plus compréhensibles aux patients et plus pertinentes aux médecins. Nous pensons que … [voir plus]

LATTICE MEDICAL develops MATTISSE, a 3D printed bioabsorbable and tissue engineered implant for breast reconstruction LATTICE MEDICAL develops a disruptive bioabsorbable and personalised implant for breast reconstruction and breast augmentation. We use an original approach combining advantages of actual reconstruction technics to give a simple surgery, more accessible to patient … [voir plus]

Mnemo Therapeutics is a biotechnology company focused on discovering and developing immune based therapies, including powerful cell therapies, that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of … [voir plus]

Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm … [voir plus]

Pioneering A New Class of Universal Vaccines Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, … [voir plus]

At the forefront of the fight against antibioresistant bacteria Pherecydes Pharma develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to fight bacterial infections in humans, particularly those resistant to antibiotics. Phages are natural predators of bacteria and have no demonstrated effect on eukaryotic cells, including human … [voir plus]

Make tissues real Poietis (gr. Ποίησις: to make). "The one who makes things real."​ Poietis develops and produces human, customized tissues using 4D bioprinting for pharmaceutical and cosmetic applications as well as regenerative medicine. Complex 3D tissues are obtained by high resolution Laser-Assisted Bioprinting. [voir plus]

Mieux soigner le cancer grâce au digital Resilience est une entreprise dédiée au suivi à distance et à l’accompagnement des patients en oncologie dont la mission est de mieux soigner le cancer grâce au digital. À travers des outils synergiques destinés aux patient·e·s et à celles et ceux qui les … [voir plus]

Pioneering thymus-empowered T-cell platform to fight cancer and infection Smart Immune is a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell progenitor therapy platform to fully and rapidly re-arm the immune system, enabling next-generation allogeneic T-cell therapies. The company is a spin-off from the Imagine Institute of Genetic Diseases, and … [voir plus]

Births can save lives StemInov is a French Drug Discovery company working on a innovative cell based therapy in immunology [voir plus]

Biomorphic Programmable Polymers TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, … [voir plus]

Cell Therapy for All TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant … [voir plus]